- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:diseases:ankylosing_spondylitis [01.11.2019] – [Standard treatments] sallieq | home:diseases:ankylosing_spondylitis [01.11.2019] – [Related research] sallieq | ||
|---|---|---|---|
| Line 40: | Line 40: | ||
| He experienced waxing and waning of symptoms both physical and emotional through the first 3 years of treatment, peaking in mid 2007. Presently he is no longer depressed and is back working full time in international finance. His prostatitis has cleared as has his IBS. Bone density increased 11% in his femur and 5% in his lumbar vertebrae over the last 2 years. His Bath Ankylosing spondylitis Disease Activity Index which had risen from 8.8 to 9.2 is now 5.3.</ | He experienced waxing and waning of symptoms both physical and emotional through the first 3 years of treatment, peaking in mid 2007. Presently he is no longer depressed and is back working full time in international finance. His prostatitis has cleared as has his IBS. Bone density increased 11% in his femur and 5% in his lumbar vertebrae over the last 2 years. His Bath Ankylosing spondylitis Disease Activity Index which had risen from 8.8 to 9.2 is now 5.3.</ | ||
| - | |||
| - | |||
| - | {{tag> | ||
| - | |||
| Line 90: | Line 86: | ||
| - | ==== Related research ==== | + | ==== Related research |
| The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset of patients after certain dental procedures were performed. These findings have important therapeutic and preventive implications. | The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset of patients after certain dental procedures were performed. These findings have important therapeutic and preventive implications. | ||
| Line 97: | Line 93: | ||
| - | + | {{tag> | |
| - | + | ||
| - | {{tag> | + | |
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
home/diseases/ankylosing_spondylitis.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.